Investigators in the Human Oncology and Pathogenesis Program (HOPP) at Memorial Sloan Kettering have one foot in the lab and one foot in the clinic. Positioned at the forefront of translational research, HOPP investigators are uniquely situated to bridge gaps between the basic science and clinical research worlds. HOPP’s research programs span multiple cancer types, and its scientists employ innovative technologies, often redefining how we find, develop, and test new cancer therapies. The program also supports graduate and postdoctoral training for physicians and scientists who want to serve at the cutting-edge of translational cancer research.

View Our Timeline of Discoveries

charles sawyers

HOPP Chair Charles Sawyers (center) with research fellows Ping Mu and Elizabeth Adams

 

Faculty & Leadership
HOPP scientists are leaders in their field and are conducting research at the cutting edge of cancer science.
View all HOPP faculty View our scientific advisory board

Education & Training

HOPP is dedicated to training physicians and scientists at all levels for careers at the forefront of translational cancer research.

Open Positions
Explore open postdoctoral positions and other career opportunities.
Learn more
Featured News & Events
View all news View all events

In the Lab

Targeting Errors in How Proteins Are Made Is a Promising Approach for Cancer Treatment

MSK studies look at the role of RNA splicing factors in acute myeloid leukemia and melanoma.

In the Lab

Scientists Create the First Human-Tumor-Derived Model for Studying Rectal Cancer

Scientists at Memorial Sloan Kettering have created a model of rectal cancer using human-tumor-derived organoids.

In the Lab

Researchers Unravel the Biology of a Distinct Prostate Cancer Subtype

Mutations in a gene called FOXA1 are responsible for a distinct class of prostate cancer tumors, MSK researchers have found.

Finding

One Patient’s Exceptional Response Leads to a Surprising Discovery about Immunotherapy

MSK researchers learn that some cancers may respond to checkpoint inhibitor drugs because of changes called gene fusions.